European Pharmaceutical Review

JANUARY 11, 2024

chronic neuropathic pain is at present, mainly managed with antidepressants… antiepileptic drugs… as well as opioids” Neuropathic pain affects over 400 million people worldwide, according to Hoba Therapeutics. He has been responsible for development programmes in multiple indications, spanning all phases of drug development.

Drug Development 102

Drug Development Medical Schools 102

European Pharmaceutical Review

MAY 8, 2024

This will help address a variety of indications with high unmet medical needs, such as autoimmune diseases, cancer, and neurological disorders. Before that, he held positions as a principal investigator at the University of Tuebingen, Germany, and a prior postdoc position at Harvard Medical School in Boston. Johannes B.

Medical Schools 98

Medical Schools Drug Development 98

European Pharmaceutical Review

DECEMBER 11, 2023

1 However, research related to RNA therapeutics has also consistently reinforced limitations that drug developers are steadfastly working to address – primarily that delivery of most RNA therapies has thus far been limited to the liver and unable to target other tissues in the body. 2017; 376:86-88. References 1. 2019;380:1.

Medical Schools 98

Medical Schools Drug Development 98

STAT

MARCH 6, 2023

A spokeswoman for the FDA said federal law prohibits regulators from commenting on pending requests to make experimental drugs available, inside or outside a clinical trial. In 2017, he was diagnosed with advanced cancer of the esophagus and told he probably had  only months to live.

Vaccines 244

Vaccines Bioethics Immunity Immunization 244